Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution.

The Karnofsky's index of performance status (KPS) and the Eastern Cooperative Oncology Group Performance Status Scale (ECOG PS) are widely used methods of assessing the functional status of cancer patients. In this study, we compare their predictive validity, and suggest a table of transformation between scales. 536 consecutive lung cancer patients were assigned both KPS and ECOG PS scores before, during and after treatment (in all, 1656 assignments). Patients were accurately staged at diagnosis, and carefully re-evaluated at each follow-up visit. Multiple clinical, laboratory and instrumental data were recorded along with performance status assessments. Survival times were measured from the pathological diagnosis. KPS and ECOG PS assignments were strongly related to each other (Spearman R = -0.869). Correlation between scales persisted unchanged in pretreatment and post-treatment assessments, advanced and limited diseases, response or non-response to treatment, and different assessors (R indices ranging from -0.825 to -0.901). A three-point conversion table showed the highest rate of success with an overall percentage of agreement exceeding 84% (grade 1: KPS = 100, 90, 80 and ECOG PS = 0, 1; grade 2: KPS = 70, 60 and ECOG PS = 2; grade 3: KPS < 60 and ECOG PS = 3, 4). Both univariate and multivariate analyses of survival documented the predictive validity of the two scales. However, KPS showed less ability than ECOG PS to discriminate patients with different prognosis. Because of the better predictive ability shown in this study, ECOG PS should be preferred to KPS. A general consensus on the scale to use could avoid problems of conversion, which is not always easy and free of errors.

[1]  A. Biggi,et al.  Imaging lung cancer by scintigraphy with indium 111‐labeled F(ab')2 fragments of the anticarcinoembryonic antigen monoclonal antibody F023C5 , 1992, Cancer.

[2]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[3]  C. Conill,et al.  Performance status assessment in cancer patients , 1990, Cancer.

[4]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[5]  D. Ferrigno,et al.  A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non‐small cell lung cancer , 1993, Cancer.

[6]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[7]  C. Conill,et al.  Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa? , 1992, European journal of cancer.

[8]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[9]  S. Capewell,et al.  Performance and prognosis in patients with lung cancer. The Edinburgh Lung Cancer Group. , 1990, Thorax.

[10]  P. Ganz,et al.  Karnofsky performance status revisited: reliability, validity, and guidelines. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Weller,et al.  International Histological Classification of Tumours , 1981 .

[12]  D. Ferrigno,et al.  A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG) , 1994, European journal of cancer.

[13]  Antonio Curcio,et al.  Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19‐9 , 1987, Cancer.

[14]  S. Siegel,et al.  Nonparametric Statistics for the Behavioral Sciences , 2022, The SAGE Encyclopedia of Research Design.

[15]  L. Laliberte,et al.  The Karnofsky performance status scale: An examination of its reliability and validity in a research setting , 1984, Cancer.

[16]  D. Karnofsky The clinical evaluation of chemotherapeutic agents in cancer , 1949 .

[17]  Emil Frei,et al.  Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide , 1960 .

[18]  D. Cox Regression Models and Life-Tables , 1972 .

[19]  J. Aisner,et al.  Performance status assessment among oncology patients: a review. , 1986, Cancer treatment reports.

[20]  Colin M. MacLeod,et al.  Evaluation of chemotherapeutic agents , 1949 .

[21]  Max H. Myers,et al.  Manual for Staging of Cancer , 1992 .

[22]  R. Cellerino,et al.  Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C , 2004, Cancer Chemotherapy and Pharmacology.

[23]  A. Biggi,et al.  Anti-CEA immunoscintigraphy might be more useful than computed tomography in the preoperative thoracic evaluation of lung cancer. A comparison between planar immunoscintigraphy, single photon emission computed tomography (SPECT), and computed tomography. , 1993, Chest.

[24]  P. Ganz,et al.  Quality of life assessment. An independent prognostic variable for survival in lung cancer , 1991, Cancer.

[25]  A. Curcio,et al.  Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma , 1986 .

[26]  H. Hansen,et al.  Performance status assessment in cancer patients. An inter-observer variability study. , 1993, British Journal of Cancer.

[27]  D. Ferrigno,et al.  Prognostic factors in lung cancer: tables and comments. , 1994, The European respiratory journal.